Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS
• FY2020 Q3 Year-to-Date Results Driven by 15% Underlying Revenue Growth of 14 Global Brands (e.g., ENTYVIO +24.0%, TAKHZYRO +38.1%, Immunoglobulin +13.7%); Generated Strong Margins and Cash Flow
• R&D Engine Continues to Advance Wave 1 Pipeline With Submission of TAK-721, the First of Seven Potential NME Filings Over Next 12 Months
• Confirming Full-Year Management Guidance and Raising Forecasts for Free Cash Flow and Reported EPS
• Purpose-Led Sustainability Commitment Drives Recent Carbon Neutrality Achievement Across Value Chain
OSAKA, Japan-Saturday 6 February 2021 [ AETOS Wire ]
(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial resul
...
Read more »